Nipah virus kills up to three-quarters of those infected, and there’s still no vaccine
Nipah has caused small, deadly outbreaks across South Asia for decades. The conditions for a larger epidemic are worsening. And despite everything learned from covid, preparations remain thin.
When covid-19 arrived, the world had no vaccine, no treatment, and no functioning global preparedness infrastructure. Five years on, mRNA vaccine platforms were built and deployed at extraordinary speed, surveillance networks were expanded, and pandemic legislation was revised in dozens of countries. The question a commentary in Science asks is whether any of that hard-won progress extends to the next candidate pathogen, and whether Nipah is it.
Nipah is a paramyxovirus, transmitted primarily by fruit bats and occasionally through pigs or human-to-human contact. Its fatality rate runs between 40 and 75 percent, depending on the outbreak and the quality of care available. It causes encephalitis, respiratory failure, and in survivors, sometimes a prolonged neurological syndrome. Outbreaks have occurred in Malaysia, Bangladesh, and India. Each time, they were contained, but not always because the virus lacked the capacity to spread further.
Why the reassurance doesn’t fully hold
The standard comfort, ‘Nipah doesn’t spread easily between people’, is partially true but potentially misleading. Multiple human-to-human transmissions have been documented in Bangladesh. Viruses evolve. A modest increase in transmissibility, combined with a mortality rate ten to fifteen times higher than covid-19’s, would produce an epidemic scenario more severe than anything seen in recent history.
The conditions enabling larger outbreaks are also worsening. Deforestation across South and Southeast Asia is pushing bat populations closer to human settlements. Intensified agriculture, pigs, fruit, and people in proximity, increases the probability of cross-species spillover. And the global connectivity that made covid spread so rapidly remains entirely intact.
What is and isn’t ready
No Nipah vaccine has been approved for human use, although candidate vaccines have reached early clinical trials. No antiviral treatments are available outside experimental settings. Diagnostics have improved but capacity remains concentrated in high-income countries, not in the South Asian regions where Nipah is most likely to emerge. Bangladesh and India have developed some surveillance capacity through painful experience, but international coordination and stockpiling remain minimal.
What covid demonstrated, at enormous cost, is that preparedness before an outbreak is exponentially cheaper than response after one. Whether that lesson has translated into political will and sustained investment for a virus like Nipah is the question the article raises. It doesn’t offer a reassuring answer.